S&P 500   3,222.56 (+0.78%)
DOW   26,829.40 (+0.70%)
QQQ   260.27 (-0.04%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,222.56 (+0.78%)
DOW   26,829.40 (+0.70%)
QQQ   260.27 (-0.04%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,222.56 (+0.78%)
DOW   26,829.40 (+0.70%)
QQQ   260.27 (-0.04%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
S&P 500   3,222.56 (+0.78%)
DOW   26,829.40 (+0.70%)
QQQ   260.27 (-0.04%)
AAPL   386.61 (-0.42%)
MSFT   205.19 (-1.52%)
GOOGL   1,503.13 (-1.17%)
AMZN   2,987.30 (-3.14%)
NVDA   402.90 (-2.93%)
BABA   247.60 (-0.39%)
TSLA   1,469.99 (-3.09%)
T   30.01 (+0.13%)
DIS   120.33 (+1.41%)
Log in

NASDAQ:PBYIPuma Biotechnology Stock Price, Forecast & News

$9.96
-0.04 (-0.40 %)
(As of 07/15/2020 12:48 PM ET)
Add
Compare
Today's Range
$9.80
Now: $9.97
$10.25
50-Day Range
$9.00
MA: $10.56
$11.85
52-Week Range
$5.50
Now: $9.97
$15.00
Volume457,373 shs
Average Volume1.51 million shs
Market Capitalization$392.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Read More
Puma Biotechnology logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.9Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$272.30 million
Book Value$0.45 per share

Profitability

Net Income$-75,600,000.00

Miscellaneous

Employees272
Market Cap$392.26 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

How has Puma Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Puma Biotechnology's stock was trading at $9.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PBYI shares have increased by 7.5% and is now trading at $9.9650. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Puma Biotechnology?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 4 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Puma Biotechnology.

When is Puma Biotechnology's next earnings date?

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Puma Biotechnology.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) posted its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.34. The biopharmaceutical company had revenue of $51.20 million for the quarter, compared to analyst estimates of $44.42 million. Puma Biotechnology had a negative net margin of 36.72% and a negative return on equity of 500.98%. The company's revenue was down 48.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.21 earnings per share. View Puma Biotechnology's earnings history.

What price target have analysts set for PBYI?

11 brokerages have issued 12 month price targets for Puma Biotechnology's shares. Their forecasts range from $6.00 to $17.00. On average, they expect Puma Biotechnology's stock price to reach $12.22 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price. View analysts' price targets for Puma Biotechnology.

Has Puma Biotechnology been receiving favorable news coverage?

News headlines about PBYI stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Puma Biotechnology earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Puma Biotechnology.

Are investors shorting Puma Biotechnology?

Puma Biotechnology saw a decline in short interest in June. As of June 15th, there was short interest totaling 7,440,000 shares, a decline of 5.6% from the May 31st total of 7,880,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 6.4 days. Approximately 22.4% of the shares of the company are short sold. View Puma Biotechnology's Current Options Chain.

Who are some of Puma Biotechnology's key competitors?

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the following people:
  • Mr. Alan H. Auerbach, Founder, Chairman, Pres, CEO & Sec. (Age 49)
  • Dr. Richard P. Bryce, Chief Medical & Scientific Officer (Age 62)
  • Mr. Steven Lo, Chief Commercial Officer (Age 52)
  • Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 71)
  • Mr. Maximo F. Nougues, CFO & Principal Accounting Officer (Age 50)

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include MERIAN GLOBAL INVESTORS UK Ltd (0.46%) and Envestnet Asset Management Inc. (0.05%). Company insiders that own Puma Biotechnology stock include Alan H Auerbach, Charles R Eyler, Douglas M Hunt, Jay M Moyes, Richard Paul Bryce and Troy Edward Wilson. View institutional ownership trends for Puma Biotechnology.

Which institutional investors are selling Puma Biotechnology stock?

PBYI stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Douglas M Hunt, Jay M Moyes, Richard Paul Bryce, and Troy Edward Wilson. View insider buying and selling activity for Puma Biotechnology.

Which institutional investors are buying Puma Biotechnology stock?

PBYI stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd. View insider buying and selling activity for Puma Biotechnology.

How do I buy shares of Puma Biotechnology?

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of PBYI stock can currently be purchased for approximately $9.97.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $392.26 million and generates $272.30 million in revenue each year. The biopharmaceutical company earns $-75,600,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Puma Biotechnology employs 272 workers across the globe.

What is Puma Biotechnology's official website?

The official website for Puma Biotechnology is www.pumabiotechnology.com.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.